Literature DB >> 19048001

Rituximab for membranous nephropathy and immune disease: less might be enough.

Piero Ruggenenti1, Paolo Cravedi, Giuseppe Remuzzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19048001     DOI： 10.1038/ncpneph1007

Source DB:  PubMed          Journal:  Nat Clin Pract Nephrol        ISSN： 1745-8323


× No keyword cloud information.
  10 in total

Review 1.  Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.

Authors:  Donald M Arnold; Francesco Dentali; Mark A Crowther; Ralph M Meyer; Richard J Cook; Christopher Sigouin; Graeme A Fraser; Wendy Lim; John G Kelton
Journal:  Ann Intern Med       Date:  2007-01-02       Impact factor: 25.391

2.  Abbreviated dose rituximab for immune-mediated hematological disorders.

Authors:  Helen Fairweather; Annabel Tuckfield; Andrew Grigg
Journal:  Am J Hematol       Date:  2008-07       Impact factor: 10.047

Review 3.  Drug insight: rituximab in renal disease and transplantation.

Authors:  Alan D Salama; Charles D Pusey
Journal:  Nat Clin Pract Nephrol       Date:  2006-04

Review 4.  Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review.

Authors:  Annalisa Perna; Arrigo Schieppati; Javier Zamora; Giovanni A Giuliano; Norbert Braun; Giuseppe Remuzzi
Journal:  Am J Kidney Dis       Date:  2004-09       Impact factor: 8.860

5.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Authors:  R John Looney; Jennifer H Anolik; Debbie Campbell; Raymond E Felgar; Faith Young; Lois J Arend; James A Sloand; Joseph Rosenblatt; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2004-08

6.  Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.

Authors:  Paolo Cravedi; Piero Ruggenenti; Maria Chiara Sghirlanzoni; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2007-08-16       Impact factor: 8.237

7.  Rituximab for idiopathic membranous nephropathy.

Authors:  Giuseppe Remuzzi; Carlos Chiurchiu; Mauro Abbate; Verusca Brusegan; Mario Bontempelli; Piero Ruggenenti
Journal:  Lancet       Date:  2002-09-21       Impact factor: 79.321

8.  Rituximab treatment of idiopathic membranous nephropathy.

Authors:  F C Fervenza; F G Cosio; S B Erickson; U Specks; A M Herzenberg; J J Dillon; N Leung; I M Cohen; D N Wochos; E Bergstralh; M Hladunewich; D C Cattran
Journal:  Kidney Int       Date:  2007-10-17       Impact factor: 10.612

9.  Rituximab in idiopathic membranous nephropathy: a one-year prospective study.

Authors:  Piero Ruggenenti; Carlos Chiurchiu; Varusca Brusegan; Mauro Abbate; Annalisa Perna; Claudia Filippi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

10.  Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.

Authors:  D Albert; J Dunham; S Khan; J Stansberry; S Kolasinski; D Tsai; S Pullman-Mooar; F Barnack; C Striebich; R J Looney; E T Luning Prak; R Kimberly; Y Zhang; R Eisenberg
Journal:  Ann Rheum Dis       Date:  2008-02-04       Impact factor: 19.103
  10 in total
  8 in total

1.  Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab.

Authors:  Maddalena Marasà; Paolo Cravedi; Barbara Ruggiero; Piero Ruggenenti
Journal:  BMJ Case Rep       Date:  2014-08-25

Review 2.  Treatment of membranous nephropathy: time for a paradigm shift.

Authors:  Piero Ruggenenti; Fernando C Fervenza; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

Review 3.  Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.

Authors:  Miaomiao Chen; Xuehan Zhang; Yi Xiong; Gaosi Xu
Journal:  Int Urol Nephrol       Date:  2022-09-25       Impact factor: 2.266

Review 4.  Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal.

Authors:  Paolo Cravedi
Journal:  Nephron       Date:  2016-09-28       Impact factor: 2.847

Review 5.  Idiopathic membranous nephropathy: management strategies.

Authors:  Marco Quaglia; Piero Stratta
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

6.  Circulating (CD3(-)CD19(+)CD20(-)IgD(-)CD27(high)CD38(high)) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?

Authors:  Agnieszka Pozdzik; Ingrid Beukinga; Chunyan Gu-Trantien; Karen Willard-Gallo; Joëlle Nortier; Olivier Pradier
Journal:  Mediators Inflamm       Date:  2016-07-14       Impact factor: 4.711

7.  Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.

Authors:  Yo Han Ahn; Seong Heon Kim; Kyoung Hee Han; Hyun Jin Choi; Heeyeon Cho; Jung Won Lee; Jae Il Shin; Min Hyun Cho; Joo Hoon Lee; Young Seo Park; Il-Soo Ha; Hae Il Cheong; Su Young Kim; Seung Joo Lee; Hee Gyung Kang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

8.  Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.

Authors:  Jorge Enrique Rojas-Rivera; Sol Carriazo; Alberto Ortiz
Journal:  Clin Kidney J       Date:  2019-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.